GLP-1 receptor agonists
US$ 24.92
weekly glp 1 agonist The Landscape Of GLP-1 Receptor Agonists In Diabetes And Obesity Treatment Glucagon-like peptide-1 receptor: mechanisms and
Description
The Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market worth USD 2.91 billion in 2026 is growing at a CAGR of 8.24% to reach USD 4.33 billion by 2031
A dual GIP/GLP-1 agonist studied in metabolic research
GLP-1 drugs like Ozempic and Mounjaro may offer real benefits for people with type 1 diabetes: less insulin, flatter CGM curves, and emerging evidence for heart and kidney protection.
Previously we have shown that GLP-1 activates afferent renal nerve to increase efferent renal sympathetic nerve activity that negates the diuresis and natriuresis as a negative feedback mechanism in normal rats
